Treatment of recurrent anterior uveitis with infliximab in patient with ankylosing spondylitis

Matsuda, Junko; Kaburaki, Toshikatsu; Kobayashi, Shigeto; Numaga, Jiro
January 2013
Japanese Journal of Ophthalmology;Jan2013, Vol. 57 Issue 1, p104
Academic Journal
Background: We describe a HLA-B27-positive Japanese man with recurrent severe anterior uveitis OU and ankylosing spondylitis (AS) who was successfully treated with infliximab. Case: A 25-year-old HLA-B27-positive Japanese man presented with recurrent anterior uveitis OU. The symptoms were consistent with typical HLA-B27-associated uveitis, whereas the subsequent course, which consisted of frequent episodes of recurrent severe anterior uveitis, was atypical. Although the patient was treated with intensive topical corticosteroids, cycloplegic treatment, sub-Tenon triamcinolone acetonide injections, systemic corticosteroids and immunosuppressive agents, recurrence of the anterior uveitis persisted. Over 8 years there were 14 documented episodes of recurrent anterior uveitis OD and 10 OSs. At age 33, the patient was diagnosed with AS after a radiographic examination. We began infusions of infliximab (2.5 mg/kg) at 0, 2 and 6 weeks, and then every 8 weeks thereafter. The recurrent uveitis disappeared, and the immunosuppressive agents and oral corticosteroids were tapered and discontinued without relapse. All drugs other than infliximab were successfully stopped in October 2010. During the follow-up period, there were no adverse events. Conclusion: A case of severe recurrent anterior uveitis OU in a patient with AS with infliximab was successfully treated. This is the first report describing the efficacy of infliximab in AS-associated uveitis in Japan.


Related Articles

  • Anti-tumour necrosis factor therapy for ankylosing spondylitis—unresolved issues. JOIS, R. N.; GAFFNEY, K.; KEAT, A. // Rheumatology;Jun2007, Vol. 46 Issue 6, p899 

    The authors comment on issues related to anti-tumour necrosis factor (TNF) therapy for ankylosing spondylitis (AS). They state that there are evidence that treatment with infliximab, etanercept and adalimumab reduces pain and stiffness and improves the sense of well-being and functional outcome...

  • Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance. WAILOO, ALLAN; BANSBACK, NICK; CHILCOTT, JIM // Rheumatology;Feb2008, Vol. 47 Issue 2, p119 

    The authors explore evidence on the cost-effectiveness of infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis (AS). They note studies commissioned by Wyeth, Abbott and Schering Plough showing that tumor necrosis factor-α inhibitors are cost-effective than...

  • Infliximab-induced lupus-like syndrome in a patient with ankylosing spondylitis. Bodur, Hatice; Eser, Filiz; Konca, Şefika; Arıkan, Serpil // Rheumatology International;Feb2009, Vol. 29 Issue 4, p451 

    Infliximab is a chimerical monoclonal antibody currently used in the treatment of various inflammatory diseases. Lupus-like syndrome is a rarely reported adverse event, and generally observed in rheumatoid arthritis cases. We hereby define and describe a case of a lupus-like syndrome, which...

  • Development of leprosy in a patient with ankylosing spondylitis during the infliximab treatment: reactivation of a latent infection? Lopes, Roberta Vilela; Ohashi, Claudia Barros; Cavaleiro, Luiza Helena; Cruz, Rosana de Britto Pereira; da Veiga, Rossana Ruth Garcia; Miranda, Mário Fernando Ribeiro; Yoshikawa, Gilberto Toshimitsu // Clinical Rheumatology;May2009, Vol. 28 Issue 5, p615 

    The use of tumor necrosis factor α as a treatment for chronic inflammatory conditions has been shown to be associated with an increased risk of developing infections, especially Mycobacterium tuberculosis, atypical mycobacteria, and other microorganisms. We report the case of a 58-year-old...

  • HLA-B27 Uveitis is the Most Common Type of Uveitis in Ethnic Chinese. Yu-Mei Chung // Current Rheumatology Reviews;2008, Vol. 4 Issue 2, p103 

    HLA-B27-associated uveitis is the most common type of endogenous uveitis in the ethnic Chinese population. The typical presentation of HLA-B27 uveitis is acute anterior uveitis (AAU). AAU has been defined as a sudden onset of pain, redness, and photophbia associated with anterior chamber cells...

  • Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis. Senabre-Gallego, José Miguel; Santos-Ramírez, Carlos; Santos-Soler, Gregorio; Salas-Heredia, Esteban; Sánchez-Barrioluengo, Mabel; Barber, Xavier; Rosas, José // Patient Preference & Adherence;2013, Vol. 7, p961 

    To date, anti-tumor necrosis factor alfa (anti-TNF-Ï°) therapy is the only alternative to nonsteroidal anti-inflammatory drugs for the treatment of ankylosing spondylitis. Etanercept is a soluble TNF receptor, with a mode of action and pharmacokinetics different to those of antibodies and...

  • Safe Long-Term In Juveniles, Too.  // BioWorld Today;11/9/2007, Vol. 18 Issue 219, p6 

    The article discusses the findings of the Review of safety and effectiveness with Adalimumab in Patients with active ankylosing spondytis (RHAPSODY) presented by Abbott during the American College of Rheumatology (ACR) meeting. Abbott reported that its anti-TNF-alpha therapy, Humira, decreases...

  • Early Diagnosis of AS or Other SpA - From Clinical and Radiologic Viewpoint. Kumar, Ashok; Das, Chandan J. // Current Rheumatology Reviews;2009, Vol. 5 Issue 3, p169 

    Until a decade ago, treatment of ankylosing spondylitis (AS) used to be quite unsatisfactory. However, the advent of TNF blockers has brought about a dramatic change in clinical approach to this disease. The long diagnostic delay- typically 7 to 10 years in the past- is no longer considered...

  • TRATAMENTUL CU INFLIXIMAB ÃŽN SPONDILITA ANCHILOZANTÄ‚. Roşca, Corina; Berghea, Florin; Abobului, M.; Vlad, Violeta; Bojincă, Violeta; Opriş, Daniela; Negru, Magda; Constantinescu, C.; Predeţeanu, Denisa; Ionescu, Ruxandra // Romanian Journal of Rheumatology;2010, Vol. 19 Issue 4, p218 

    Infliximab (IFX) is an IgG1k anti TNFa chimerical monoclonal antibody. Presuming that TNFa is a key-element implied in the autoimmune reaction in ankylosing spondylitis (AS), several clinical studies have shown a rapid effect, sustained efficacy, the stop of the radiological progression,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics